![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche's GLP1/GIP drug sees 22.5%](https://a.storyblok.com/f/176343/1920x1281/8abca57422/roche_270585.jpeg)
glp-1 roche
Shipping Estimate
glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche's GLP1/GIP drug sees 22.5%
EUR26.69
EUR69.69
Pay in 4 interest-free payments of $6.67 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche's GLP1/GIP drug sees 22.5%](https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1812040254%20%281%29.jpg?VersionId=idd_CDc5t_JQ44nQ1BNBX6PQ__RT5x2Q)
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche's GLP1/GIP drug sees 22.5%](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3455611900453475204)
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche's GLP1/GIP drug sees 22.5%](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3822283803747020876)
![glp-1 roche Ad hoc announcement pursuant to Art. 53 LR] announces positive Phase I results of its oral receptor agonist CT-996 for the treatment of people with obesity Roche's GLP1/GIP drug sees 22.5%](https://i.ytimg.com/vi/aVwCFzy7fdg/hq720.jpg?sqp=-oaymwEhCK4FEIIDSFryq4qpAxMIARUAAAAAGAElAADIQj0AgKJD&rs=AOn4CLABDIGmlZGMT5pIwGH8LZKf4ftTkg)
